BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22273502)

  • 1. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
    Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
    BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
    Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
    Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
    Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive biomarkers for bevacizumab in anti-tumor therapy].
    Pan Q; Wang M
    Zhongguo Fei Ai Za Zhi; 2011 Jul; 14(7):606-12. PubMed ID: 21762631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
    J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy.
    Kara O; Duman BB; Kara B; Erdogan S; Parsak CK; Sakman G
    Asian Pac J Cancer Prev; 2012; 13(12):6397-401. PubMed ID: 23464465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screening for predictive biomarkers of bevacizumab treatment in gastric cancer subcutaneous xenografts].
    Zhang Q; Xu J; Ye J; Yuan Y; Chen J; Peng J; He Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Feb; 18(2):177-80. PubMed ID: 25656129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.
    Singh R; Kim WJ; Kim PH; Hong HJ
    Exp Mol Med; 2013 Nov; 45(11):e52. PubMed ID: 24176949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
    Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
    Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer.
    Peng CL; Lin HC; Chiang WL; Shih YH; Chiang PF; Luo TY; Cheng CC; Shieh MJ
    Photodiagnosis Photodyn Ther; 2018 Sep; 23():111-118. PubMed ID: 29894822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
    Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
    Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
    Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
    Han ES; Burger RA; Darcy KM; Sill MW; Randall LM; Chase D; Parmakhtiar B; Monk BJ; Greer BE; Connelly P; Degeest K; Fruehauf JP
    Gynecol Oncol; 2010 Dec; 119(3):484-90. PubMed ID: 20870280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor a inhibition in gastric cancer.
    Park DJ; Thomas NJ; Yoon C; Yoon SS
    Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
    Pavlidis ET; Pavlidis TE
    World J Gastroenterol; 2013 Aug; 19(31):5051-60. PubMed ID: 23964138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
    Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.